Search results
Results from the WOW.Com Content Network
Venter (and Smith)'s previous company, Celera Genomics, was a driving force in the race to sequence the human genome. [9] The firm takes its name from the phrase synthetic genomics which is a scientific discipline of synthetic biology related to the generation of organisms artificially using genetic material. [10] [11]
Zymergen was founded in 2013. [5] by investment banker Joshua Hoffman, biophysicist Zach Serber, and biochemist Jed Dean. [6]All three met while working at Amyris, Inc. [7] The company uses machine learning and artificial intelligence to study and modify microbes which ferment carbon [6] to produce chemicals used in manufacturing consumer goods and pharmaceuticals. [8]
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology.
While it's easy to think the industry will only have a major impact in industrial applications, at companies such as 3 Synthetic Biology Stocks That Can Help You Grow in 2014 (and Beyond) Skip to ...
For premium support please call: 800-290-4726 more ways to reach us
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The field of synthetic biology has not been good to investors. But maybe we've just been looking in the wrong places. 3 Companies That Don't Seem Like Synthetic Biology Stocks, but Actually Are
The company provides an extensive range of products for the synthetic biology industry, such as CRISPR & Gene editing tools. To meet the growing demand for biopharmaceuticals and biotechnological resources, Merck undertakes investments in biomanufacturing technologies that boost the capacity and productivity of biological production processes.